Mixed trend on the daily chart: above its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Sep 24 · inside the Ichimoku cloud · RSI 46 · MACD above its signal · at its 52-week high
| 0.000100 | Price now | |
| 0.000100 | R3 (classic) | −0.00% |
| 0.000100 | R2 (classic) | −0.00% |
| 0.000100 | R1 (classic) | −0.00% |
| 0.000100 | Pivot | −0.00% |
| 0.000100 | S1 (classic) | −0.00% |
| 0.000100 | S2 (classic) | −0.00% |
| 0.000100 | S3 (classic) | −0.00% |
| 0.000100 | Previous day high | −0.00% |
| 0.000100 | Previous day low | −0.00% |
| 0.000100 | Previous week high | −0.00% |
| 0.000100 | Previous week low | −0.00% |
| 0.000100 | Previous month high | −0.00% |
| 0.000100 | Previous month low | −0.00% |
| 0.000100 | 52-week high | −0.00% |
| 0.000100 | 52-week low | −0.00% |
None of the 29 investors followed here reported a position in HDII in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a HDII trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
No insider transactions reported for HDII.
No analyst coverage for this instrument.
Hypertension Diagnostics, Inc. designs, develops, manufactures, and markets proprietary noninvasive medical devices that detect subtle changes in the elasticity of arteries in the United States and internationally. It offers CVProfilor, which allows a physician to non-invasively assess the elasticity of small and large arteries, of which small artery elasticity is the earliest and sensitive marker of cardiovascular disease. The company offers CVProfilor DO-2020, which provides a patient's arterial elasticity indices used in the assessment for underlying vascular disease; CVProfilor MD-3000 that offers a sensitive and specific guide to the presence of blood vessel disease; and HD/PulseWave CR-2000 research cardiovascular profiling system, which provides researchers and scientists with a non-invasive means to assess arterial elasticity in support of human research in various areas. Its products collect 30 seconds of blood pressure waveform data, perform an analysis of the digitized blood pressure waveforms, and generate a CVProfile report that contains information on blood pressure, heart rate, pulse pressure, body surface area, body mass index, and C1-large and C2-small artery elasticity indices. The company sells its products to primary care physicians, cardiologists, health care professionals, trained medical personnel, research investigators at academic medical research centers, government institutes, cardiovascular specialists, and pharmaceutical firms. It markets its products through a representative organization in the United States. Hypertension Diagnostics, Inc. was founded in 1988 and is based in Richmond Hill, Canada.
No recent headlines.
TimeframesDown on the monthly, mixed on the daily and weekly.
pulling back under the 21 EMA
pulling back under the 21 EMA
under a falling 21 EMA, 21 under 50
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0% | ||
| 2025 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0% |
| 2024 | 0.0 | 0.0 | 0.0 | -80.0 | -50.0 | 0.0 | 0.0 | 100.0 | -50.0 | 0.0 | 0.0 | 0.0 | −90.0% |
| 2023 | 8.3 | 53.8 | -30.0 | 10.7 | -54.8 | -21.4 | 0.0 | 45.5 | 12.5 | 0.0 | -44.4 | 0.0 | −58.3% |
| 2022 | 4.6 | 2.5 | -7.3 | -19.7 | -24.6 | 32.6 | -17.2 | -16.8 | -7.1 | -35.9 | 44.0 | -33.3 | −68.6% |
| 2021 | 120.0 | -1.8 | -25.9 | -35.2 | -11.7 | 18.1 | -7.9 | -26.4 | -2.3 | 44.0 | -44.4 | -23.5 | −56.3% |
| 2020 | -38.3 | 74.2 | 40.2 | -36.7 | 680.7 | -11.2 | -3.9 | 6.1 | -60.3 | -38.2 | 26.9 | -47.0 | +11.3% |
| 2019 | -7.7 | 41.7 | 5.9 | -13.9 | 519.4 | -3.1 | -36.6 | 18.6 | 100.0 | 17.9 | 9.1 | -12.6 | +1110.0% |
| 2018 | -65.0 | -14.3 | 0.0 | 318.3 | -0.4 | 652.0 | 43.6 | 33.3 | -25.3 | -84.2 | -52.9 | -35.0 | −35.0% |
| 2017 | -3.3 | 3.4 | -20.0 | 2.1 | 2.0 | -60.0 | 0.0 | 200.0 | -63.3 | 0.0 | -27.3 | 150.0 | −33.3% |
| 2016 | 0.0 | -17.6 | 0.0 | -7.1 | 53.8 | 0.0 | 0.0 | -25.0 | 0.0 | 66.7 | -16.0 | 42.9 | +76.5% |
| 2015 | -35.0 | -37.7 | -3.7 | 15.4 | 0.0 | -17.8 | -18.9 | 50.0 | -55.6 | 0.0 | -47.5 | -19.0 | −91.5% |
| 2014 | -15.8 | -25.0 | -16.7 | 2.0 | 94.1 | 11.1 | 54.5 | -29.4 | -16.7 | 50.0 | 0.7 | 32.5 | +110.5% |
| 2013 | 83.1 | -23.1 | 50.0 | 113.3 | -37.5 | -11.5 | -54.8 | -6.3 | 62.7 | 39.3 | -38.2 | -9.5 | +33.8% |
| 2012 | -29.4 | 16.7 | -8.6 | -42.2 | -32.4 | -4.0 | 23.7 | 68.4 | -24.0 | -50.0 | -21.1 | -52.7 | −91.6% |
| 2011 | -25.0 | 11.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -15.0 | -11.8 | 13.3 | −29.2% |
| 2010 | 25.0 | -16.0 | -10.1 | 2.9 | 2.9 | -11.1 | -12.5 | -21.4 | -17.5 | 4.0 | 37.7 | -7.7 | −33.3% |
| 2009 | -40.0 | 23.3 | -45.9 | 25.0 | 0.0 | 4.0 | 46.2 | 142.1 | 52.2 | -28.6 | 10.0 | 63.6 | +260.0% |
| 2008 | 57.1 | -10.9 | 7.1 | -23.8 | 25.0 | -10.0 | -44.4 | 0.0 | -20.0 | -7.5 | 2.7 | 31.6 | −28.6% |
| 2007 | 1.5 | 12.8 | -12.0 | 17.4 | -12.9 | -14.8 | 13.0 | 53.8 | -10.0 | -8.3 | -27.3 | -41.7 | −46.6% |